Literature DB >> 29225272

Tumor Emboli from Aortic Metastasis.

Yohei Ikebe1, Eijun Sueyoshi1, Hideki Ishimaru1, Masaaki Hidaka2.   

Abstract

Entities:  

Keywords:  aorta; emboli; imaging; metastasis

Year:  2017        PMID: 29225272      PMCID: PMC5891538          DOI: 10.2169/internalmedicine.9696-17

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
The patient was a 67-year-old man with cholangiocarcinoma who underwent partial hepatectomy. At 34 months after surgery, descending aortic wall thickening was observed on contrast-enhanced CT (Picture A and B). Fluorodeoxyglucose positron emission tomography (FDG-PET) scans showed an increased uptake in this lesion (Picture G).
Picture.
Thereafter, the aortic wall thickness gradually increased, and the wall of the superior mesenteric artery (SMA) also thickened (Picture C and D). After 6 months, a CT scan was performed because of severe abdominal pain. As wall thickening of the SMA had partly disappeared, part of the lesion was suggested to be an embolus (Picture E and F; arrow). Angiography demonstrated total occlusion of the SMA (Picture H; arrow). Thromboaspiration was immediately performed using a catheter. A pathological analysis of the embolus demonstrated tumor emboli from cholangiocarcinoma metastasis (Picture I). Aortic metastasis is very rare. Similarly to cases involving primary aortic tumors, arterial tumor embolization in cases involving aortic metastasis is a clinical problem (1,2). The authors state that they have no Conflict of Interest (COI).
  2 in total

1.  Dissection of the ascending aorta due to metastatic carcinoma.

Authors:  B S Ugurlu; E Hazan; O Badak; K Yörükoğlu; O Oto
Journal:  Ann Thorac Surg       Date:  2001-08       Impact factor: 4.330

2.  Concealed primary aortic sarcoma induced hypertensive encephalopathy resulting from a thoracic aortic occlusion: a case report.

Authors:  Hyunmin Choi; Hee-Jeoung Yoon; Woo-Ik Jang; Chang-Young Kim; Joon-Hyung Doh
Journal:  J Cardiothorac Surg       Date:  2013-04-18       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.